News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
683,794 Results
Type
Article (39461)
Company Profile (207)
Press Release (644126)
Section
Business (205729)
Career Advice (2017)
Deals (35781)
Drug Delivery (77)
Drug Development (81774)
Employer Resources (171)
FDA (15996)
Job Trends (15065)
News (347555)
Policy (32699)
Tag
Academia (2544)
Africa (731)
Alabama (32)
Allergies (37)
Alliances (49651)
Alzheimer's disease (1117)
Antibody-drug conjugate (ADC) (46)
Approvals (15938)
Arizona (161)
Artificial intelligence (51)
Asia (37840)
Australia (6084)
Bankruptcy (353)
Best Places to Work (11280)
Biosimilars (56)
C2C Services and Suppliers (79056)
California (826)
Canada (644)
Cancer (177)
Career advice (1682)
CAR-T (33)
Cell therapy (67)
China (50)
Clinical research (63603)
Collaboration (58)
Colorado (34)
COVID-19 (2475)
Cystic fibrosis (70)
Diabetes (32)
Diagnostics (5907)
Diversity, equity & inclusion (45)
Drug pricing (50)
Earnings (83763)
Employer resources (145)
Europe (81268)
Events (109244)
FDA (16042)
Florida (106)
Funding (37)
Gene therapy (53)
GLP-1 (489)
Government (4309)
Healthcare (18603)
Hotbed/Location (485544)
Idaho (55)
Illinois (194)
Indiana (105)
Infectious disease (2488)
Inflammatory bowel disease (85)
Interviews (322)
IPO (16346)
Job creations (3823)
Job search strategy (1454)
Kansas (90)
Layoffs (384)
Legal (7863)
Liver cancer (51)
Lung cancer (37)
Maine (47)
Management (53)
Manufacturing (47)
Maryland (255)
Massachusetts (455)
Medical device (12959)
Medtech (12962)
Mergers & acquisitions (19132)
Metabolic disorders (160)
Neuroscience (1197)
New Jersey (62)
New York (83)
NextGen Class of 2024 (6491)
Non-profit (4460)
North Carolina (167)
Obesity (103)
Opinion (175)
Patents (33)
Peanut (33)
Pennsylvania (55)
People (56356)
Phase I (19756)
Phase II (28079)
Phase III (20871)
Podcasts (43)
Policy (36)
Postmarket research (2554)
Preclinical (8417)
Rare diseases (90)
Real estate (5999)
Recruiting (65)
Regulatory (21255)
Reports (32)
Research institute (2320)
Resumes & cover letters (348)
South America (1110)
Startups (3628)
Texas (87)
United States (3036)
Vaccines (419)
Washington State (114)
Weight loss (101)
Date
Today (13)
Last 7 days (501)
Last 30 days (1812)
Last 365 days (38794)
2024 (21939)
2023 (40659)
2022 (51785)
2021 (56342)
2020 (54540)
2019 (46985)
2018 (35387)
2017 (32637)
2016 (32060)
2015 (38112)
2014 (32005)
2013 (26894)
2012 (29013)
2011 (29668)
2010 (27706)
683,794 Results for "landos biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
AbbVie Completes Acquisition of Landos Biopharma
AbbVie announced that it has completed its acquisition of Landos Biopharma, Inc.
May 23, 2024
·
4 min read
Deals
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
March 25, 2024
·
9 min read
Business
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
Landos Biopharma, Inc. today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.
March 21, 2024
·
7 min read
Deals
NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
The NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for autoimmune diseases, today recognized its co-founders, Dr. Josep Bassaganya-Riera and Dr. Raquel Hontecillas, and scientific director Dr. Andrew Leber for their leadership in the discovery and development of NX-13 that enabled today’s acquisition of Landos Biopharma, Inc. (“Landos”) by AbbVie, Inc. (NYSE: ABBV) (“AbbVie”).
March 25, 2024
·
8 min read
Business
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
Landos Biopharma, Inc. provided a business update and announced financial results for the quarter ended September 30, 2023.
November 9, 2023
·
7 min read
BioCapital
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced that six abstracts were accepted for poster presentation at the 19th Annual Congress of the European Crohn’s and Colitis Organisation.
January 8, 2024
·
5 min read
Deals
AbbVie Acquires Landos in Potential $212M Deal, Bolsters Anti-Inflammatory Pipeline
Monday’s announced buyout of Virginia-based Landos Biopharma adds a mid-stage, oral NLRX1 agonist for ulcerative colitis and Crohn’s disease to AbbVie’s growing portfolio.
March 25, 2024
·
1 min read
·
Kate Goodwin
Pharm Country
Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting
Landos Biopharma, Inc. today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada.
October 23, 2023
·
4 min read
Business
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
Landos Biopharma, Inc. today provided a business update and announced financial results for the second quarter ended June 30, 2023.
August 9, 2023
·
6 min read
Drug Development
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis
Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a peer-reviewed publication describing the safety, tolerability, pharmacokinetic and clinical efficacy results for the NX-13 Phase 1b trial in patients with ulcerative colitis (UC) in the Journal of Crohn’s and Colitis.
November 21, 2023
·
4 min read
1 of 68,380
Next